

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4922202

| | | |
|---|--|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | ASSIGNMENT | |
| CONVEYING PARTY DATA | | |
| | Name | Execution Date |
| | UNITRACT SYRINGE PTY LTD | 07/24/2017 |
| RECEIVING PARTY DATA | | |
| Name: | HIKMA PHARMACEUTICALS LLC | |
| Street Address: | BAYADER WADI AL-SEER, INDUSTRIAL AREA, SALEEM BIN AL-HARETH STREET, BUILDING 21, P.O. BOX 182400 | |
| City: | AMMAN | |
| State/Country: | JORDAN | |
| Postal Code: | 11118 | |
| PROPERTY NUMBERS Total: 3 | | |
| Property Type | Number | |
| Application Number: | 14453354 | |
| Application Number: | 14454172 | |
| Application Number: | 15354712 | |
| CORRESPONDENCE DATA | | |
| Fax Number: | (202)719-7049 | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | |
| Phone: | 202.719.7000 | |
| Email: | PTODOCKET@WILEYREIN.COM | |
| Correspondent Name: | WILEY REIN LLP | |
| Address Line 1: | 1776 K STREET, NW | |
| Address Line 2: | PATENT ADMINISTRATION | |
| Address Line 4: | WASHINGTON, D.C. 20006 | |
| ATTORNEY DOCKET NUMBER: | 88093.2US; 80093.3US-US1 | |
| NAME OF SUBMITTER: | LAWRENCE M. SUNG | |
| SIGNATURE: | /Lawrence M. Sung/ | |
| DATE SIGNED: | 04/18/2018 | |
| Total Attachments: 6 | | |
| source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page1.tif | | |
| source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page2.tif | | |

source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page3.tif
source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page4.tif
source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page5.tif
source=88093_0002US_24JUL2017_Executed_Patent_Assignment_Agreement#page6.tif

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (the "Assignment") dated as of July 24, 2017, is made by and between (i) Unilife Medical Solutions, Inc., a corporation organized under the laws of Delaware, U.S.A., with its principal place of business at 250 Cross Farm Lane, York, Pennsylvania 17406, U.S.A. ("Unilife"), (ii) Unitract Syringe Pty Ltd ACN 101 059 723, a Western Australia company ("Unitract" and together with Unilife, the "Assignors"), and Hikma Pharmaceuticals LLC, a company registered in Jordan with its principal place of business at Bayader Wadi Al-Seer, Industrial Area, Saleem Bin Al-Hareth Street, Building 21, P.O. Box 182400, Amman, 11118, Jordan ("Assignee").

WITNESSETH:

WHEREAS, Assignors and Assignee entered into that certain Asset Purchase Agreement, dated as of July 20, 2017 (the "Acquisition Agreement"); and

WHEREAS, pursuant to the Acquisition Agreement, Assignee shall purchase and accept and Assignor shall transfer and assign to Assignee all of Assignors' right, title and interest in, to and under certain of Assignors' patents and patent applications, including those listed in Schedule A hereto (the "Patents"), together with all patents issuing thereon and any extensions or restorations by existing or future extension or restoration mechanisms, including without limitation Supplementary Protection Certificates or the equivalents thereof, renewals, continuations, continuations in part, divisionals, patents of addition, certificates of invention, extensions, substitutions, confirmations, re-registrations, re-examinations, revalidations and/or reissues of any patent, and any foreign counterparts thereof.

NOW, THEREFORE, in consideration of the premises and covenants set forth herein and in the Acquisition Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Section 1.1 Assignment. Assignors hereby sell, transfer, convey, assign and deliver to Assignee, and Assignee hereby purchases and accepts from Assignors, all of Assignors' right, title and interest in and to the Patents, including, but not limited to, the exclusive rights to (a) bring actions, defend against or otherwise recover for infringements, and the right to the profits or damages due or accrued, arising out of or in connection with any and all past, present or future infringements of the Patents, (b) apply for, make filings with respect to and maintain all issuances, renewals and extensions thereof, and (c) all other rights of any kind whatsoever of Assignors accruing thereunder.

Section 1.2 Acknowledgement. Assignors hereby acknowledge and agree that from and after the date hereof, as between the parties, Assignee shall be the exclusive owner of the Patents.

Section 1.3 Cooperation. This Assignment has been executed and delivered by the Assignors for the purpose of recording the assignment herein with the appropriate government entity.

Section 1.4 Power of Attorney. The Assignors further appoint Assignee as their true and lawful attorney-in-fact and agent as of the date set forth below for their use and benefit to effect the terms of this Assignment and to perfect Assignee's right, title and interest in and to the Patents, including, without limitation, to prepare, execute in the undersigned Assignors' names and on the undersigned's behalf, and submit to the proper authority any and all documents necessary or desirable to effectuate, confirm, file and/or record a transfer or assignment to the Assignee of all worldwide rights in and to the Patents, and all power of attorney documents, agreements or other documents relating to the registration, application, maintenance, opposition, cancellation or assignment of all worldwide rights in and to the Patents, including all necessary additions, associations, amendments, conversion, division, interview, licensing, pledging, change of name etc., and applications for re-examination; and to sign Assignors' names upon all filings and to do all things necessary to maintain and register the Patents with the applicable patent offices, agencies, and registrars in all applicable jurisdictions. Assignors hereby grant to such attorney-in-fact full irrevocable power and authority in the place of Assignors and in the name of either Assignor or in its own name as nominee for either Assignor, to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and delegation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The power of attorney granted pursuant to this Section 1.4, is coupled with an interest and as such is irrevocable and will not be affected by subsequent dissolution, termination of existence or any other event concerning, the Assignors.

Section 1.5 EXCLUSION OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THE ACQUISITION AGREEMENT, THERE ARE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THIS ASSIGNMENT OR THE SUBJECT MATTER HEREOF, AND ANY REPRESENTATIONS OR WARRANTIES RELATING TO THIS ASSIGNMENT OR THE SUBJECT MATTER HEREOF ARE HEREBY DISCLAIMED.

Section 1.6 General Provisions. The provisions in the sections Governing Law, Miscellaneous Provisions, and Interpretative Matters of the Acquisition Agreement are incorporated herein by reference and shall apply to this Assignment.

[Signature Page Follows]

Executed by Unitract Syringe Pty Ltd ACN 101 059 723 in accordance with s127 of the Corporations Act 2001:

.....
Signature of director

.....
Signature of director/company secretary

.....STEPHANIE WALTERS
Name of director (print)

.....JOHN RYAN
Name of director/company secretary (print)

STATE OF PA)

: ss.:

COUNTY OF Montgomery

On the 24th day of July 2017, before me the undersigned, personally appeared Stephanie Walters + John C Ryan, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

.....
Notary Public

COMMONWEALTH OF PENNSYLVANIA
NOTARIAL SEAL
ANDREW P. STANKIEWICZ, Notary Public
Radnor Township, Delaware County
My Commission Expires August 24, 2019

[Signature Page to Patent Assignment Agreement]

(BAY:03087688v1)

PATENT
REEL: 045579 FRAME: 0863

SIGNED for and on behalf of Hikma
Pharmaceuticals LLC

m. Lahady *M. Mishawi*

Name: *Majda Ali Mishawi*
Title: *Director*
Date: *20 July 2017*

SIGNED for and on behalf of Hikma
Pharmaceuticals LLC

Tamir Darwazeh

Name: *Tamir Darwazeh*
Title: *Authorized Signatory*
Date: *20 July 2017*

[Signature Page to Patent Assignment Agreement]

{BAY:03087688v1}

Schedule A - Patents

- (1) U.S. Provisional Patent Application 61/863,098
- (2) U.S. Provisional Patent Application 61/898077
- (3) International Patent Application PCT/US2014/049962
- (4) International Patent Application PCT/US14/50116
- (5) U.S. Patent Application No. 14/453,354
- (6) U.S. Patent Application No. 14/454,172
- (7) U.S. Patent Application No. 15/354,712

{BAY:03087688v1}